Latest Vertex Pharmaceuticals Inc (VRTX) Headlines
The Spark of Innovation at Vertex Pharmaceuticals Incorporated
Max Macaluso, The Motley Fool - Motley Fool - Fri Mar 07, 5:30PM CST
There's little room for error in the biotech industry. The discovery and development of new drugs is a long, arduous process that sometimes takes a decade to complete, and precision is necessary at every step. From synthesizing a compound in the...
The Ever-Changing Hepatitis C Space
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 07, 4:15PM CST
Without a doubt, the launch of Gilead Sciences ' hepatitis C drug Sovaldi has been stellar. While very early, the drug has performed better than Vertex Pharmaceuticals ' Incivek, which reached $1 billion in sales in less than a year after it...
Stocks Open Higher, Turn Mixed After Employment Report
at Investor's Business Daily - Fri Mar 07, 9:31AM CST
Stocks opened higher Friday, then backtracked to mixed terrain as drugmakers and some leading stocks added drag in early trade. The Dow Jones industrial average remained ahead 0.4%. The S&P 500 was up 0.2% and the Nasdaq slipped 0.2%. Celgene (CELG),...
Vertex Pharmaceuticals Up 14.6% Since SmarTrend Uptrend Call (VRTX)
Comtex SmarTrend(R) - Fri Mar 07, 9:28AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on November 29th, 2013 at $69.75. In approximately 3 months, Vertex Pharmaceuticals has returned 14.59% as of today's recent price of $79.92.
Vertex Pharmaceuticals (VRTX) Is Today's Roof Leaker Stock
at The Street - Fri Mar 07, 9:21AM CST
Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 3.64% Sell Off
Comtex SmarTrend(R) - Thu Mar 06, 5:09PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $79.33 to a high of $83.59. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $79.57 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Vertex Pharmaceuticals to Potentially Rebound After Falling 3.64% Yesterday
Comtex SmarTrend(R) - Thu Mar 06, 5:08PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $79.33 to a high of $83.59. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $79.57 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Vertex to Present at the Barclays Global Healthcare Conference on March 11
Business Wire - Thu Mar 06, 3:25PM CST
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Barclays Global Healthcare Conference on Tuesday, March 11 at 8:00 a.m. ET.
4 Keys to Vertex Pharmaceuticals' Success
Max Macaluso, The Motley Fool - Motley Fool - Mon Mar 03, 8:39AM CST
Over the last 10 years, shares of Vertex Pharmaceuticals have soared more than 635%. That growth was driven by ground-breaking clinical research and successful FDA drug approvals, but success stories like this are exceedingly rare in the biotech...
20.7% Return Seen to Date on SmarTrend Vertex Pharmaceuticals Call (VRTX)
Comtex SmarTrend(R) - Thu Feb 27, 9:22AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on November 29th, 2013 at $69.75. In approximately 3 months, Vertex Pharmaceuticals has returned 20.70% as of today's recent price of $84.18.
Xeltis Completes Enrollment in World's First Study of Spontaneous Tissue Growth Technology; Early Follow-up Shows Promise in Children with Congenital Heart Defect
Business Wire - Thu Feb 27, 6:00AM CST
Xeltis, a privately held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has finished enrollment in a five-patient feasibility study of implantable products intended to enable for the first time the spontaneous growth of natural, healthy heart valves and vessels. With its proprietary technology, the company has pioneered an entirely new therapeutic category called Endogenous Tissue Growth, or ETG, in which surgeons use unique implants designed to allow the body to repair itself by growing natural, healthy tissue.
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Essex Rental Corp. Announces Modification of Revolving Credit Facility
Business Wire - Wed Feb 26, 6:47AM CST
Essex Rental Corp. (Nasdaq: ESSX) ("Essex") today announced that it entered into an amendment to its Coast Crane credit agreement. The modification to the credit agreement provides Essex with greater flexibility to capitalize on opportunities to increase revenues associated with the sale of new equipment. The modification also amends language in the existing credit agreement related to the application of asset sale proceeds from new and used equipment sales.
5 Monster Momentum Stocks to Trade
at The Street - Tue Feb 25, 1:23PM CST
Momentum traders and trend-following traders are basking in profits in this current market.
3 Stocks Pushing The Health Care Sector Higher
at The Street - Tue Feb 25, 11:02AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
3 Things to Watch at Gilead
Brian Orelli, The Motley Fool - Motley Fool - Mon Feb 24, 8:53PM CST
A large portion of Gilead Sciences ' future growth will come from its new hepatitis C drug Sovaldi, and drug cocktails that contain the drug, which are currently under review at the FDA. Here are three topics that investors should keep their eyes...
Top 8 Developed CF Markets to Post 30.4% CAGR Through 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Mon Feb 24, 12:03PM CST
In 2012, the combined value of the cystic fibrosis (CF) therapeutics markets in the top 8 developed economies stood at around USD 696.5 million. It is predicted to grow considerably in the years ahead, registering a 30.4% CAGR, and is forecast to amount to almost USD 4.5 billion in 2019. The market's primary growth stimulator is the introduction of new treatment options with disease-modifying mechanisms of action. The favourable impact of novel market entrants is expected to offset the negative effects of key patent losses in the next 5 years.
Vertex' Kalydeco Approved for an Additional Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 12:00PM CST
Vertex Pharma received encouraging news when the FDA approved Kalydeco for an additional indication.
Vertex Pharmaceuticals wins US Food and Drug Administration's approval for KALYDECO for use in eight additional mutations that cause cystic fibrosis
M2 - Mon Feb 24, 5:08AM CST
Biotechnology company Vertex Pharmaceuticals (NasdaqGS:VRTX) revealed on Friday the receipt of approval from the the US Food and Drug Administration (FDA) for supplemental New Drug Application (sNDA) for KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages six and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
U.S. Food and Drug Administration Approves KALYDECO(TM) (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis
Business Wire - Fri Feb 21, 1:55PM CST
---KALYDECO facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein-
The Spark of Innovation at Vertex Pharmaceuticals Incorporated
Max Macaluso, The Motley Fool - Motley Fool - Fri Mar 07, 5:30PM CST
There's little room for error in the biotech industry. The discovery and development of new drugs is a long, arduous process that sometimes takes a decade to complete, and precision is necessary at every step. From synthesizing a compound in the...
The Ever-Changing Hepatitis C Space
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 07, 4:15PM CST
Without a doubt, the launch of Gilead Sciences ' hepatitis C drug Sovaldi has been stellar. While very early, the drug has performed better than Vertex Pharmaceuticals ' Incivek, which reached $1 billion in sales in less than a year after it...
Stocks Open Higher, Turn Mixed After Employment Report
at Investor's Business Daily - Fri Mar 07, 9:31AM CST
Stocks opened higher Friday, then backtracked to mixed terrain as drugmakers and some leading stocks added drag in early trade. The Dow Jones industrial average remained ahead 0.4%. The S&P 500 was up 0.2% and the Nasdaq slipped 0.2%. Celgene (CELG),...
Vertex Pharmaceuticals Up 14.6% Since SmarTrend Uptrend Call (VRTX)
Comtex SmarTrend(R) - Fri Mar 07, 9:28AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on November 29th, 2013 at $69.75. In approximately 3 months, Vertex Pharmaceuticals has returned 14.59% as of today's recent price of $79.92.
Vertex Pharmaceuticals (VRTX) Is Today's Roof Leaker Stock
at The Street - Fri Mar 07, 9:21AM CST
Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 3.64% Sell Off
Comtex SmarTrend(R) - Thu Mar 06, 5:09PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $79.33 to a high of $83.59. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $79.57 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Vertex Pharmaceuticals to Potentially Rebound After Falling 3.64% Yesterday
Comtex SmarTrend(R) - Thu Mar 06, 5:08PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $79.33 to a high of $83.59. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $79.57 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Vertex to Present at the Barclays Global Healthcare Conference on March 11
Business Wire - Thu Mar 06, 3:25PM CST
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Barclays Global Healthcare Conference on Tuesday, March 11 at 8:00 a.m. ET.
4 Keys to Vertex Pharmaceuticals' Success
Max Macaluso, The Motley Fool - Motley Fool - Mon Mar 03, 8:39AM CST
Over the last 10 years, shares of Vertex Pharmaceuticals have soared more than 635%. That growth was driven by ground-breaking clinical research and successful FDA drug approvals, but success stories like this are exceedingly rare in the biotech...
20.7% Return Seen to Date on SmarTrend Vertex Pharmaceuticals Call (VRTX)
Comtex SmarTrend(R) - Thu Feb 27, 9:22AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on November 29th, 2013 at $69.75. In approximately 3 months, Vertex Pharmaceuticals has returned 20.70% as of today's recent price of $84.18.
Xeltis Completes Enrollment in World's First Study of Spontaneous Tissue Growth Technology; Early Follow-up Shows Promise in Children with Congenital Heart Defect
Business Wire - Thu Feb 27, 6:00AM CST
Xeltis, a privately held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has finished enrollment in a five-patient feasibility study of implantable products intended to enable for the first time the spontaneous growth of natural, healthy heart valves and vessels. With its proprietary technology, the company has pioneered an entirely new therapeutic category called Endogenous Tissue Growth, or ETG, in which surgeons use unique implants designed to allow the body to repair itself by growing natural, healthy tissue.
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Essex Rental Corp. Announces Modification of Revolving Credit Facility
Business Wire - Wed Feb 26, 6:47AM CST
Essex Rental Corp. (Nasdaq: ESSX) ("Essex") today announced that it entered into an amendment to its Coast Crane credit agreement. The modification to the credit agreement provides Essex with greater flexibility to capitalize on opportunities to increase revenues associated with the sale of new equipment. The modification also amends language in the existing credit agreement related to the application of asset sale proceeds from new and used equipment sales.
5 Monster Momentum Stocks to Trade
at The Street - Tue Feb 25, 1:23PM CST
Momentum traders and trend-following traders are basking in profits in this current market.
3 Stocks Pushing The Health Care Sector Higher
at The Street - Tue Feb 25, 11:02AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
3 Things to Watch at Gilead
Brian Orelli, The Motley Fool - Motley Fool - Mon Feb 24, 8:53PM CST
A large portion of Gilead Sciences ' future growth will come from its new hepatitis C drug Sovaldi, and drug cocktails that contain the drug, which are currently under review at the FDA. Here are three topics that investors should keep their eyes...
Top 8 Developed CF Markets to Post 30.4% CAGR Through 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Mon Feb 24, 12:03PM CST
In 2012, the combined value of the cystic fibrosis (CF) therapeutics markets in the top 8 developed economies stood at around USD 696.5 million. It is predicted to grow considerably in the years ahead, registering a 30.4% CAGR, and is forecast to amount to almost USD 4.5 billion in 2019. The market's primary growth stimulator is the introduction of new treatment options with disease-modifying mechanisms of action. The favourable impact of novel market entrants is expected to offset the negative effects of key patent losses in the next 5 years.
Vertex' Kalydeco Approved for an Additional Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 12:00PM CST
Vertex Pharma received encouraging news when the FDA approved Kalydeco for an additional indication.
Vertex Pharmaceuticals wins US Food and Drug Administration's approval for KALYDECO for use in eight additional mutations that cause cystic fibrosis
M2 - Mon Feb 24, 5:08AM CST
Biotechnology company Vertex Pharmaceuticals (NasdaqGS:VRTX) revealed on Friday the receipt of approval from the the US Food and Drug Administration (FDA) for supplemental New Drug Application (sNDA) for KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages six and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
U.S. Food and Drug Administration Approves KALYDECO(TM) (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis
Business Wire - Fri Feb 21, 1:55PM CST
---KALYDECO facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein-
